熱門資訊> 正文
Apogee Therapeutics报告第二季度业绩
2024-08-12 18:46
- Apogee Therapeutics press release (NASDAQ:APGE): Q2 net loss of $33.8 million, compared to the net loss for the second quarter of 2023 which was $18.9 million.
- Net loss increased primarily as a result of higher R&D and G&A expenses as described above, partially offset by higher interest income.
More on Apogee Therapeutics
- Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
- Seeking Alpha’s Quant Rating on Apogee Therapeutics
- Historical earnings data for Apogee Therapeutics
- Financial information for Apogee Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
